Longeveron Inc. Class A LGVN

By Brad Sorensen, CFA NASDAQ: LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron’s (NASDAQ: LGVN) September 16 announcement represents an important turning point for the company. The Phase 2b ELPIS II trial of laromestrocel in hypoplastic left heart syndrome, or HLHS, failed to meet its primary efficacy endpoint, a result that understandably caused a sharp reset in investor expectations. The

Stephen Willard Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN) Company Announces Exploration of All Options to Maximize Shareholder Value The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular ejection fraction (RVEF) at month 12, but there were exploratory clinical endpoints that the Company is continuing to analyze and plans to discuss with the FDA to determine a potential path forward in HLHSLaromestrocel has

MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference taking place September 14-16, 2026 in New York City. Details for the Company’s presentation: Date:Monday, September 14, 2026 Time:1:00 – 1:30 p.m. ET The webcast for this

Stephen Willard Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN) MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectivel

Nirav Jhaveri, Chief Financial Officer Nirav Jhaveri, Chief Financial Officer Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Com

By Brad Sorensen, CFA NASDAQ: LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ: LGVN) is entering what may be the most consequential period in its history. The clinical-stage biotechnology company is developing laromestrocel, a proprietary allogeneic cell therapy derived from bone marrow mesenchymal stem cells from young, healthy adult donors. Rather than relying on separate drugs for

Moby summary of Longeveron Inc.'s Q2 2026 earnings call

Stephen Willard Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN) On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indicationLongeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results which indicated laromestrocel increas

Stephen Willard Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN) Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron Longeveron selected as a Milestone 2 Awardee based on published clinical trial results which demonstrated laromestrocel increased 6-minute walk distance in patients with Aging-related Frailty MIAMI, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical-stage regenerative medicine biote

MIAMI, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report 2026 second quarter financial results and provide a business update on Wednesday, August 12, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call

Dr. Ascheim has over 30 years of clinical and executive experience advancing breakthrough therapies, including gene, cell, and biologics Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron Deborah D. Ascheim, M.D. Deborah D. Ascheim, M.D. MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related c

Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC) entitled “Laromestrocel Stabilizes Brain Inflammation In Key Alzheimer’s Disease Gray And White Matter Regions As Assessed Using Free Water MRI” presented at July 13th In Person Poster Presentation SessionResults support a clinically relevant and long-lasting anti-inflammatory mechanism of action of l